ABSTRACT: Toll-like receptor (TLR)-8 agonists strongly induce the production of T helper 1-polarizing cytokines and may therefore serve as promising candidate vaccine adjuvants, especially for the very young and the elderly. Earlier structure-based ligand design led to the identification of 3-pentyl-quinoline-2-amine as a novel, human TLR8-specific agonist. Comprehensive structure−activity relationships in ring-contracted 1-alkyl-1H-benzimidazol-2-amines were undertaken, and the best-in-class compound, 4-methyl-1-pentyl-1H-benzo[d]imidazol-2-amine, was found to be a pure TLR8 agonist, evoking strong proinflammatory cytokine and Type II interferon responses in human PBMCs, with no attendant CD69 upregulation in natural lymphocytic subsets. The 1-alkyl-1H-benzimidazol-2-amines represent a novel, alternate chemotype with pure TLR8-agonistic activities and will likely prove useful not only in understanding TLR8 signaling but also perhaps as a candidate vaccine adjuvant.
■ INTRODUCTION
Although the role of vaccines in mitigating morbidity and mortality attributable to infectious diseases in modern times is indisputable, 1, 2 we are witnessing a reemergence of infectious diseases previously declared eliminated in the United States. The Centers for Disease Control, for instance, reports 154 cases of measles during the first four months of 2014, a number poised to surpass the 2011 outbreak (the largest since 1996)even as the recent World Health Organization (WHO) report 3 on antimicrobial resistance warns that "a post-antibiotic era, in which common infections and minor injuries can killfar from being an apocalyptic fantasy, is instead a very real possibility for the 21st Century". We can neither afford to rest on the numerous and extraordinary successes in preventive medicine nor cease to remind ourselves of the challenges that are yet to be overcome in developing effective vaccines against "old foes" such as the human immunodeficiency virus (HIV), tuberculosis, or malaria.
The main thrust of immunization programs worldwide is generally on vaccinating infants and young children, and it is pertinent to note in this context the WHO's efforts 4 toward developing policy recommendations regarding immunization beyond childhood and into old age. The elderly represent a particularly vulnerable subset of the population. The proportion of the world's population aged 60 and older is estimated to increase from 10% at present to about 21% by 2050. 5 In the United States, the annual mortality of vaccine-preventable diseases in older adults is estimated to be about 50,000− 70,000 (compared to 1000−3000 children), 5, 6 emphasizing the need for effective immunization strategies adapted specifically for the epidemiological characteristics of the spectrum of infectious diseases in the elderly. Efforts toward optimizing vaccines for the elderly have included increasing antigen dosage 7 as well as the development of better vaccine adjuvants. 8, 9 Vaccine adjuvants are immune potentiators which initiate early innate immune responses leading to the induction of robust and long-lasting adaptive immune responses. 10−14 Until the relatively recent approval of 3-O-desacyl-4′-monophosphoryl lipid A (MPL) by the FDA, 15−17 aluminum salts (primarily phosphate and hydroxide), discovered by Glenny and co-workers in 1926, 18 have been the only adjuvants in clinical use. Aluminum salts are weak adjuvants for antibody induction, promoting a T H 2-skewed, rather than a T H 1 response, 19, 20 and are virtually ineffective at inducing cytotoxic T lymphocyte or mucosal IgA antibody responses.
Innate immune signals activated by candidate vaccine adjuvants include those originating from Toll-like receptors (TLRs) 21−23 as well as RIG-I-like receptors 24 and NOD-like receptors (NLRs). 25, 26 There are 10 functional TLRs encoded in the human genome, which are trans-membrane proteins with an extracellular domain having leucine-rich repeats (LRR) and a cytosolic domain called the Toll/IL-1 receptor (TIR) domain. 22 The ligands for these receptors are highly conserved molecules such as lipopolysaccharides (LPS) (recognized by TLR4, also the target of MPL), lipopeptides (TLR2 in combination with TLR1 or TLR6), flagellin (TLR5), single stranded RNA (TLR7 and TLR8), double stranded RNA (TLR3), CpG motif-containing DNA (recognized by TLR9), and profilin present on uropathogenic bacteria (TLR11). 22 TLR1, -2, -4, -5, and -6 recognize extracellular stimuli, while TLR3, -7, -8, and -9 function within the endolysosomal compartment. The activation of TLRs by their cognate ligands leads to production of inflammatory cytokines and up-regulation of major histocompatibility complex (MHC) molecules and costimulatory signals in antigenpresenting cells as well as activating natural killer (NK) cells (innate immune response), which leads to the priming and amplification of T-, and B-cell effector functions (adaptive immune responses). 21, 22, 27 In the course of the last five years we have systematically explored 28 −45 a variety of TLR agonists with a view to identifying safe and potent vaccine adjuvants. The chemotypes that we have explored thus far include agonists of TLR2, 30, 37, 40, 41 TLR7, 29, 34, 35, 38, 42, 43, 46 TLR8, 28, 31, 32, 36, 46 and nucleotide oligomerization domain 1 (NOD1) 39 as well as C−C chemokine receptor type 1 (CCR1). 33 Our interest in small molecule agonists of TLR8 as vaccine adjuvants was, in part, kindled by the necessity of having to first identify chemotypes with pure TLR8 activity, given that the known agonists of TLR8 such as the imidazoquinolines, 43, 46, 47 thiazoloquinolines, 31,48−51 and the 2-aminobenzazepines 52 were found to exhibit mixed TLR7/TLR8-agonism. Our discovery of the 2,3-diamino-furo [2,3-c] pyridines 36 and 4-amino-furo-[2,3-c]quinolines, 32 leading to structure-based design of the 3-alkyl-quinoline-2-amines 28 as pure TLR8 agonists with no detectable TLR7 activity, was also motivated by observations that the strongly Th1-biasing TLR8 agonists could be useful as candidate vaccine adjuvants for the newborn. 53, 54 Maternal immunoglobulins acquired by passive transplacental passage confer protection to the neonate for the first few weeks of life; 55 thereafter, the newborn is susceptible to a wide range of pathogens until early infancy. The very young do not mount adequate adaptive immune responses and, consequently, even highly effective vaccines that confer excellent protection in adults may fail to elicit strong immune responses in them. 56, 57 The neonatal immunophenotype is characterized by decreased production of both type I and type II interferons, as well as Th1-biasing cytokines such as TNF-α, IL-12, IL-18, IL-23, the preferential induction of memory B lymphocytes rather than immunoglobulin-secreting plasma cells, as well as a pronounced T-helper type 2 (Th2) skewing of T-cell responses. 58, 59 TLR8 agonists induce the production of IL-12, IL-18 and IFN-γ 28, 31, 32 and may therefore be of value in developing vaccines for the neonate.
Our initial interest in TLR8 agonists as candidate adjuvants has been sustained also by observations of impaired TLR signaling 60−62 contributing to immune senescence 63−65 in aging. In particular, substantial decreases in TNF-α, IL-6, and/or IL12p40 production have been documented in myeloid dendritic cells isolated from older individuals in response to TLR8 engagement, 60−62 reflecting parallels in immune ontogeny of TLR-driven cytokine responses between the very young and the agedperhaps an echo of Shakespeare's characterization of the "Seventh Age".
A high-resolution (1.8 Å) structure of human TLR8 co-crystallized with a pure TLR8-agonistic lead compound (C2-butyl-furo[2,3-c]quinoline) suggested that the furan ring was dispensable and led to the identification of 3-pentylquinoline-2-amine as a novel, structurally simple, and highly potent human TLR8-specific agonist. 28 We now report detailed structure−activity relationships in the ring-contracted 1-alkyl-1H-benzimidazol-2-amines. The best-in-class compound of this novel chemotype, 4-methyl-1-pentyl-1H-benzo[d]imidazol-2-amine, was found to retain a pure TLR8 agonistic activity profile.
■ RESULTS AND DISCUSSION
With 3-pentyl-quinoline-2-amine as our point of departure, we initially targeted the ring-contracted 2-amino-3-alkylindole analogue 4, accessed via sequential C-alkylation of commercially available 2-nitrophenylacetonitrile, reduction of the 2-nitro group, and Brønsted acid-promoted, microwave-assisted intramolecular cyclization (Scheme 1). The hydrochloride salt of 4 was isolated and found to be inactive; its free-base, however, was exceedingly unstable, leading to the rapid formation of the overoxidized 3-ol derivative 5, presumably via autoxidation 66 (Scheme 1), which was also inactive in primary screens.
We therefore focused our attention on stable analogues possessing structural scaffolds similar to the 2-aminoindole 4 and began our investigations with 1-alkyl-2-aminobenzimidazole analogues (Scheme 2). The 2-aminobenzimidazole scaffold was conveniently accessed via the reaction of o-phenylenediamine with cyanogen bromide (CNBr). The N1 position could be selectively derivatized (Scheme 2), furnishing analogues that we were particularly interested in. In a focused SAR assessment of these analogues, a clear dependence of substituent chain length at N1 was noted, consistent with our previous observations on other chemotypes, with the optimal analogue being 8b (N1-pentyl; EC 50 = 3.23 μM; Figure 1 ). We specifically desired to examine analogues with benzyl (8d) and 3-aminomethylbenzyl (8f) substituents at N1, Scheme 1 a for these substituents on the imidazoquinoline scaffold had yielded high-potency pure TLR7 and mixed TLR8/7 agonists, respectively. 43 Somewhat to our surprise, we found that neither 8d nor 8f were active; substitution of the N1-pentyl group with butoxycarbonyl group (9) or acylation of the N2 amine (10) also completely abrogated activity, suggestive of stringent structural requirements for activity and demonstrating that both the free amine at C2 and the N1 pentyl substituent are important for TLR8-agonistic activity.
We addressed modifications on the benzimidazole core, mindful of our previous observations of benzologues of imidazo [4,5-c] pyridines showing specific TLR7 activity. 29 We therefore synthesized all possible regioisomeric benzologues of 8b (Scheme 3). The naphtho-[2,3-d]imidazole analogue 13 was accessed readily via cyclization of the naphthalene-2,3-diamine with CNBr. The symmetry-related regioisomers 18 and 23 could, in principle, have been obtained from the rather expensive 1,2-diaminonaphthalene, followed by resolution of the regioisomers. But given the near-identical R f values (and retention times in analytical HPLC) of these two regioisomers, we were fortunate (in hindsight) to have opted for an alternative route. We had originally envisaged a sequence of chlorination of 1-nitronaphthalen-2-ol and 2-nitronaphthalen-1-ol precursors, nucleophilic substitution with pentylamine, and subsequent formation of the aminoimidazole ring; however, conversion of the nitronaphthols to corresponding chloronitronaphols proved unexpectedly problematic. This was alleviated by conversion to the nitromethoxynaphthols 15 and 20, which underwent facile nucleophilic substitution reactions with pentylamine, affording the desired regioisomers 18 and 23 in good yields (Scheme 3). Of the three different regioisomers, only 23 (EC 50 = 3.16 μM) showed near-identical activity to that of 8b (Table 1 ). These observations, taken together, also suggested that substitutions could be tolerated at C4 and C5, but not at C6 and C7, which were borne out as described below.
We next targeted all possible regioisomers of imidazopyridines (27a−d) for possible TLR7/8 activity, given that these analogues are congeneric to the imidazo [4,5-c] pyridines 29 (Scheme 4). These analogues were synthesized via S N Ar reactions of corresponding o-halonitropyridines with pentylamine, reduction of the nitro group, and final cyclization with CNBr (Scheme 4). None of these analogues were active, and it remained for us to explore substitutions on the benzimidazole core. In our final salvo, therefore, we systematically introduced methyl substituents at C4−C7 positions (31a−d, Scheme 5) to ascertain steric effects of the benzimidazole ring and their consequences on biological activity. Only 31a, with a C4-methyl group showed significantly more potent activity (EC 50 = 1.13 μM), relative to the parent compound 8b; the potency was comparable to that of C2-butyl-furo [2,3-c] quinoline 32 and marginally less than that of 3-pentyl-quinoline-2-amine 28 ( Figure 1) . We also examined different electron-donating and -withdrawing substituents at C4 position. The methoxy analogue 31e (EC 50 = 3.74 μM) showed comparable activity to that of 8b but was less active than 31a (Table 1) . Electron-withdrawing substitutions (31f−i) resulted in inactive compounds. Homologation of the methyl group at C4 to the ethyl-substituted analogue 31j (accomplished via Suzuki coupling of 3-bromo-2-nitro-N-pentylaniline with ethylboronic acid and subsequent elaboration; Scheme 5) resulted in a slight reduction in TLR8-agonistic potency compared to 31a, alerting us to the possibility that longer (or bulkier) substituents would not be favorable and, indeed, phenyl (31l), benzyl (31m), or benzyloxy (35) substituents at C4 abrogated activity. The electron-deficient 4-nitro analogue 39 (Scheme 7) was inactive, and analogues with electron-donating groups at C4 (31k, 36, 40; Schemes 5−7) displayed attenuated potency relative to the 4-methyl compound 31a (Table 1) .
We employed induced-fit docking methods 32 to compare the binding modes of the 2-aminobenzimidazole analogues with known TLR8 ligands, utilizing high-resolution crystal structures of human TLR8. 28, 67 The TLR8-active analogues such as 8b and Scheme 2 a 31a occupy the binding pocket formed by both of the TLR8 protomers with the expected binding geometry involving strong bidentate ionic H bonds between Asp543 of TLR8 and both the C2 amine as well as the N3 atom of the benzimidazole compounds ( Figure 2 ). Stabilization derived from an H bond between Thr574 (protomer B) and the C2-NH 2 as well as hydrophobic interactions of the N1-alkyl group with the hydrophobic pocket lined by Phe346/Ile403/Gly376 within protomer A were also observed as reported earlier. 28 Favorable π−π interactions of the phenyl ring of the bezimidazoles and Phe405 were observed. We were, in particular, interested in understanding why only the C4-methyl analogue 31a, and not congeners bearing methyl groups at C5, C6, or C7 (31b−d, respectively), showed enhanced potency relative to 8b. An examination of 31a bound to TLR8 showed favorable van der Waals interactions (3.7 Å) between the C4-methyl and the side chain of Val520 (Figure 2A ), which become unfavorable (5.2 Å) in the C5-methyl analogue 31b and lost entirely in 31c and 31d (not shown). The occupancy of the benzologues 13, 18 and 23 in the binding pocket is compromised by unfavorable sterics, exemplified in the case of 13, forcing the binding of the analogue in an inverted fashion with the consequent loss of the critical H-bond interactions between the C2 amine and Asp543 ( Figure 2B ). As detailed above, the docking studies allowed a rationalization of binding activities in terms of steric properties of the analogues but proved less useful in understanding electronic effects. For instance, favorable binding geometries and energies were also observed for the inactive pyridyl analogues 27a−d, pointing to limitations inherent in force field computations. 68 All analogues were counter-screened in agonism screens using reporter cell lines specific for human TLR2, TLR3, TLR4, TLR5, TLR7, TLR9, NOD1, and NOD2 ( Figures S1 and S2) . No offtarget effects were detected, confirming the specificity of the active analogues for human TLR8. Certain benzimidazoles such as Noditinib-1 69 (1-[(4-methylphenyl)sulfonyl]-1H-benzimidazol-2-amine) have been shown to inhibit NOD-1 signaling, and it was therefore of interest to also characterize possible antagonistic activities. Weak antagonistic activities (IC 50 : >10 μM) toward NOD-1 and NOD-2 were observed for 10, 13, 18, 31l, 31m, and 35 ( Figure S3) ; these results suggested that bulky substituents at C4 may yield NOD-1/NOD-2 antagonists but were not a priority for us in the context of discovering novel vaccine adjuvants.
The best-in-class of this novel TLR8-agonistic chemotype, 31a was taken forward and characterized further in cytokine/ chemokine induction profiles in a panel of secondary screens employing human peripheral blood mononuclear cells, as well as whole human blood. Consistent with its specificity for TLR8, we observed induction of proinflammatory cytokines, as well as IL-12p40 and IFN-γ (Figure 3) , and a complete absence of CD69 upregulation in NK lymphocytes ( Figure 4) . We had previously shown that CD69 upregulation in NK cells is ascribable purely to TLR7 activity, 28, 32 and these results confirm absolute specificity of the lead 2-aminobenzimidazole compounds for human TLR8. CD69 is a type II C-lectin membrane receptor with immunoregulatory functions. 70, 71 The absence of CD69 (in CD69 knockout mice) is correlated with increased generation of Th1 lymphocytes and enhanced production of Th1-biasing cytokines, 72, 73 consistent with our observation of induction of high levels of IL-12 and IFN-γ in human PBMCs (Figure 4) .
In summary, the 1-alkyl-1H-benzimidazol-2-amines represent a novel chemotype with human TLR8-specific agonistic activities, which will likely prove useful not only as tools to dissect TLR7 vis-a-vis TLR8 signaling but also as candidate vaccine adjuvants with strong Th1 bias.
■ EXPERIMENTAL SECTION
Chemistry. All of the solvents and reagents used were obtained commercially and used as such unless noted otherwise. Moisture-or airsensitive reactions were conducted under nitrogen atmosphere in ovendried (120°C) glass apparatus. Solvents were removed under reduced pressure using standard rotary evaporators. Flash column chromatography was carried out using RediSep Rf "Gold" high-performance silica columns on CombiFlash R f instruments unless otherwise mentioned, while thin-layer chromatography was carried out on silica gel CCM precoated aluminum sheets. Purity for all final compounds was confirmed to be >98% by LC-MS using a Zorbax Eclipse Plus 4.6 × 150 mm, 5 μm analytical reverse phase C 18 column with H 2 O-CH 3 CN and H 2 O-MeOH gradients and an Agilent 6520 ESI-QTOF Accurate Mass spectrometer (mass accuracy of 5 ppm) operating in the positive ion acquisition mode.
2-(2-Nitrophenyl)hexanenitrile (2) . To a solution of 2-nitrophenylacetonitrile (162 mg, 1 mmol) in anhydrous DMSO (5 mL) was added K 2 CO 3 (152 mg, 1.1 mmol), and the reaction mixture was stirred Scheme 3 a for 10 min under nitrogen atmosphere. Butyl iodide (125 μL, 1.1 mmol) was added to the reaction mixture, and the stirring was continued for 3 h. Water was added to the reaction mixture, and it was extracted with EtOAc (3 × 20 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (10% EtOAc/hexanes) to afford (3) . To a solution of compound 2 (109 mg, 0.5 mmol) in anhydrous EtOAc (10 mL) was added a catalytic amount of Pt/C (39 mg, 1 mol %), and the reaction mixture was subjected to hydrogenation at 30 psi hydrogen pressure for 3 h. The reaction mixture was filtered, and the filtrate concentrated under reduced pressure. The crude material was purified using silica gel column chromatography (10% MeOH/CH 2 Cl 2 ) to obtain 3 as a pale 2-Amino-3-butyl-3H-indol-3-ol (5). To a solution of compound 3 (38 mg, 0.2 mmol) in anhydrous dioxane (1 mL) was added 4 N HCl/dioxane (0.1 mL). The reaction mixture was then heated under (7). To a solution of compound o-phenylenediamine (108 mg, 1 mmol) in 1:1 mixture of MeOH (5 mL) and water (5 mL) was added CNBr (318 mg, 3 mmol). The reaction mixture was stirred for 3 h at 60°C. The reaction mixture was cooled to room temperature, the MeOH was removed under reduced pressure, and the remaining mixture was basified with 1.0 M aq. NaOH (to pH = 8.0) and extracted with EtOAc (3 × 30 mL). The combined organic layer was dried over Na 2 SO 4 , concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (20% MeOH/CH 2 Cl 2 ) to obtain the compound 7 as a white solid (109 mg, 82%). R f = 0. 20 
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To a solution of 2-aminobenzimidazole (7) (27 mg, 0.2 mmol) in acetone (1 mL) were added KOH (22 mg, 0.4 mmol) and butyl iodide (23 μL, 0.2 mmol). The reaction mixture was stirred for 3 h at 60°C. The reaction mixture was cooled to room temperature, and the solvent was removed under reduced pressure. The reaction mixture was diluted with water and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (20% MeOH/CH 2 Cl 2 ) to obtain the compound 8a as a white solid (28 mg, 74%). R f = 0. 45 
. To a solution of compound 8e (25 mg, 0.1 mmol) in THF (2 mL) was added LiAlH 4 (0.4 mL, 0.4 mmol, 1.0 M inTHF) at 0°C under nitrogen atmosphere. The reaction mixture was stirred for 1 h at 25°C and 5 h at 75°C. The reaction mixture was cooled to room temperature and quenched carefully with ice-cold water. The resulting mixture was basified with 10% NaOH (to pH = 8.0) and extracted with CH 2 Cl 2 (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by neutral-alumina column chromatography (30% MeOH/ CH 2 Cl 2 ) to obtain the compound 8f as a white solid (17 mg, 67%). (9) . To a solution of 2-aminobenzimidazole (7) (27 mg, 0.2 mmol) in anhydrous THF (2 mL) was added butyl chloroformate (27 μL, 0.2 mmol) under nitrogen atmosphere. The reaction mixture was stirred for 3 h. The reaction mixture was diluted with water and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (20% MeOH/CH 2 Cl 2 ) to afford the compound 9 as a white solid (28 mg, 60% (10) . To a stirred solution of compound 8b (41 mg, 0.2 mmol) in pyridine (2 mL) was added acetyl chloride (14 μL, 0.2 mmol). The reaction mixture was stirred for 3 h. The solvent was removed under reduced pressure. The reaction mixture was diluted with water and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (10% MeOH/CH 2 Cl 2 ) to afford the compound 10 as a white solid (32 mg, 65%). R f = 0. 62 1-Methoxy-2-nitronaphthalene (15) . To a solution of compound 2-nitro-1-naphthol (189 mg, 1 mmol) in acetone (5 mL) were added KOH (168 mg, 3 mmol) and MeI (124 μL, 2 mmol). The reaction mixture was refluxed for 12 h. The reaction mixture was cooled to room temperature, and solvent was removed under reduced pressure. Water was then added to the reaction mixture and extracted with EtOAc (3 × 30 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (10% EtOAc/hexanes) to obtain the compound 15 as a pale yellow solid (178 mg, 88%). R f = 0.50 (10% EtOAc/hexanes). 1 2-Nitro-N-pentylnaphthalen-1-amine (16) . To a solution of compound 15 (102 mg, 0.5 mmol) in DMF (3 mL) was added amyl amine (87 μL, 0.75 mmol). The reaction mixture was stirred for 10 h at 60°C. The reaction mixture was diluted with water and extracted with EtOAc (3 × 20 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (10% EtOAc/hexanes) to obtain the compound 16 as a red solid (115 mg, 89%). R f = 0.62 (10% EtOAc/hexanes). (18) . To a solution of compound 16 (52 mg, 0.2 mmol) in anhydrous EtOAc (5 mL) was added a catalytic amount of 5% Pt on carbon (16 mg, 2 mol %). The reaction mixture was subjected to hydrogenation at 30 psi H 2 pressure for 3 h. The reaction mixture was filtered, and the filtrate was concentrated under the reduced pressure to obtain compound 17. To a solution of compound 17 in a 1:1 mixture of MeOH (1 mL) and water (1 mL) was added CNBr (64 mg, 0.6 mmol). The reaction mixture was stirred for 3 h at 60°C. The reaction mixture was cooled to room temperature, and MeOH removed under reduced pressure. The remaining mixture was basified with 1.0 M aq. NaOH (to pH = 8.0) and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (10% MeOH/CH 2 Cl 2 ) to obtain the compound 18 as a purple solid (35 mg, 69%). R f = 0. 45 2-Nitro-N-pentylpyridin-3-amine (25a). To a solution of compound 3-fluoro-2-nitropyridine (142 mg, 1 mmol) in DMSO (2 mL) were added amyl amine (116 μL, 1 mmol) and DIPEA (174 μL, 1 mmol). The reaction mixture was stirred for 6 h at 60°C. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc (3 × 20 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by flash chromatography (10% EtOAc/hexanes) to afford the compound 25a as a yellow oil (184 mg, 88%). R f = 0.30 (10% EtOAc/hexanes). 1 Compounds 29a−29i were synthesized similarly as compound 25a. 3-Fluoro-2-nitro-N-pentylaniline (29f). 1, 3-Difluoro-2-nitrobenzene was used as reagent. Red oil (169 mg, 75%). R f = 0.62 (5% EtOAc/ hexanes). 2-Nitro-N-pentyl-3-(trifluoromethyl)aniline (29h). 1-Chloro-2-nitro-3-(trifluoromethyl) benzene was used as reagent. Orange solid (179 mg, 65%). R f = 0.70 (5% EtOAc/hexanes). 3-Ethyl-2-nitro-N-pentylaniline (29j). To a stirred solution of compound 29i (144 mg, 0.5 mmol) in 1,4-dioxane (3 mL) were added ethylboronic acid (56 mg, 0.75 mmol), Pd(dppf)Cl 2 (36 mg, 0.05 mmol), and K 2 CO 3 (207 mg, 1.5 mmol). The resulting reaction mixture was stirred at 90°C under nitrogen atmosphere for 12 h. The reaction mixture was diluted with water and extracted with EtOAc (3 × 20 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and crude material was purified by flash chromatography (10% EtOAc/hexanes) to obtain the compound 29j as a red oil (72 mg, 61%). R f = 0.70 (10% EtOAc/hexanes). N,N-Dimethyl-2-nitro-N′-pentyl-benzene-1,3-diamine (29k). To a solution of compound 29g (242 mg, 1 mmol) in DMF (3 mL) was added dimethyl amine (2 mL, 4 mmol, 2.0 M in MeOH). The reaction mixture was stirred for 12 h at 75°C. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 × 30 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (10% EtOAc/hexanes) to obtain the compound 29k as a red solid (200 mg, 80%). 1-Benzyloxy-3-fluoro-2-nitro-benzene (32) . To a solution of compound 28f (318 mg, 2 mmol) in DMF (10 mL) were added K 2 CO 3 (552 mg, 4 mmol) and benzyl alcohol (226 μL, 2.2 mmol). The reaction mixture was stirred for 12 h at 60°C. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 × 30 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (10% EtOAc/hexanes) to obtain the compound 32 as yellow oil (400 mg, 81%). R f = 0.2 (10% EtOAc/hexanes). (38) . To a solution of compound 37 (153 mg, 1 mmol) in DMF (5 mL) were added K 2 CO 3 (276 mg, 2 mmol) and 1-iodopentane (143 μL, 1.1 mmol). The reaction mixture was stirred for 12 h at 50°C. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 × 10 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (5% EtOAc/hexanes) to obtain the compound 38 as a red solid (120 mg, 54%). R f = 0.5 (10% EtOAc/hexanes). 1 4-Nitro-1-pentyl-1H-benzoimidazol-2-ylamine (39) . To a solution of compound 38 (45 mg, 0.2 mmol) in 1:1 mixture of MeOH (1 mL) and water (1 mL) was added CNBr (63 mg, 0.6 mmol). The reaction mixture was stirred for 3 h at 60°C. The reaction mixture was cooled to room temperature, the MeOH was removed under reduced pressure, and the remaining mixture was basified with 1.0 M aq. NaOH (to pH = 8.0) and extracted with EtOAc (3 × 20 mL). The combined organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure, and the crude material was purified by silica gel column chromatography (30% EtOAc/CH 2 Cl 2 ) to obtain the compound 39 as a yellow solid (40 mg, 81%). R f = 0.5 (10% MeOH/CH 2 Cl 2 ). (40) . To a solution of compound 39 (25 mg, 0.1 mmol) in anhydrous EtOAc (10 mL) was added a catalytic amount of Pt/C, and the reaction mixture was subjected to hydrogenation at 30 psi for 3 h. The reaction mixture was filtered, and the filtrate concentrated under reduced pressure. The crude material was purified using silica gel column chromatography (20% MeOH/CH 2 Cl 2 ) to obtain 40 as off-white solid (16 mg, 74%). 74, 75 were used as reported earlier 32 for induced fit docking. Correct bond orders were assigned, hydrogen atoms were added to the residues, and formal partial charges were assigned to atoms using OPLS-all atom force field. 76 The docking grid was generated using co-crystallized ligand as grid center. Ligands were modeled in Schrodinger molecular modeling software (Schrodinger, New York, NY) and were minimized to a gradient of 0.001KCal/MolÅ 2 . The QM charges for ligands were obtained from Jaguar (Schrodinger), using the 3-21G basis set with the BLYP density functional theory. 77 Initial docking was performed with Glide 78 using 0.5 van der Waals (vdW) radius scaling factor for both ligand and protein. This soft docking procedure was applied to generate diverse docking solutions, and top 20 poses for each ligand were retained. Finally, each ligand was redocked into its corresponding structures, and the resulting complexes were ranked according to GlideScore. 79 Human TLR-2/-3/-4/-5/-7/-8/-9 and NOD-1/-2 Reporter Gene Assays (NF-κB Induction). The induction of NF-κB was quantified using human TLR-2/3/-4/-5/-7/-8/-9-and NOD-1/NOD-2-specific, rapid-throughput, liquid handler-assisted reporter gene assays as previously described by us. 31, 33, 37, 39, 43 HEK293 cells stably cotransfected with the appropriate hTLR (or NOD) and secreted alkaline phosphatase (sAP) were maintained in HEK-Blue Selection medium. Stable expression of secreted alkaline phosphatase (sAP) under control of NF-κB/AP-1 promoters is inducible by appropriate TLR/NOD agonists, and extracellular sAP in the supernatant is proportional to NF-κB induction. Reporter cells were incubated at a density of ∼10 5 cells/ml in a volume of 80 μL/well, in 384-well, flat-bottomed, cell culturetreated microtiter plates in the presence of graded concentrations of stimuli. sAP was assayed spectrophotometrically using an alkaline phosphatase-specific chromogen (present in HEK-detection medium as supplied by the vendor) at 620 nm. Antagonistic activities were examined by incubating human NOD-1/-2 reporter cells with graded concentrations of test compounds in the presence of 100 ng/mL of C 12 -iE-DAP 39 or 10 μg/mL murabutide 45 (NOD-2). Immunoassays for Cytokines. Fresh human peripheral blood mononuclear cells (hPBMC) were isolated from human blood obtained by venipuncture with informed consent and as per institutional guidelines on Ficoll-Hypaque gradients as described elsewhere. 28 Aliquots of PBMCs (10 5 cells in 100 μL/well) were stimulated for 12 h with graded concentrations of test compounds. Supernatants were isolated by centrifugation and were assayed in duplicates using analyte-specific multiplexed cytokine/chemokine bead array assays as reported by us previously. 28 Flow-Cytometric Immunostimulation Experiments. CD69 upregulation was determined by flow cytometry using protocols published by us previously. 28, 32 Briefly, heparin-anticoagulated whole blood samples were obtained by venipuncture from healthy human volunteers with informed consent and as per guidelines approved by the University of Kansas Human Subjects Experimentation Committee. Aliquots of whole human blood samples were stimulated with graded concentrations of 31a, reference compound(s), or medium (negative control) in 96-well polypropylene plates and incubated at 37°C overnight. . Following staining, erythrocytes were lysed and leukocytes fixed in one step using Whole Blood Lyse/Fix Buffer (Becton-Dickinson Biosciences, San Jose, CA). Flow cytometry was performed using a BD FACSArray instrument on 100,000 gated events. Postacquisition analyses were performed using FlowJo v 7.0 software (Treestar, Ashland, OR).
